Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis

doi:10.4254/wjh.v14.i6.1248

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3431)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

150

WORD

HTML

1540

Figures (1-3)

429

Tables (1-2)

270

Sum=2424

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

243

Download

764

Sum=1007

Jun 27, 2022 (publication date) through Apr 27, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Hepatol. Jun 27, 2022; 14(6): 1248-1257
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1248

Open in New Tab Full Size Figure Download Figure

Figure 1 Sustained virological response by intention-to-treat analysis from sofosbuvir/velpatasvir with or without ribavirin. SOF/VEL: Sofosbuvir/velpatasvir; RBV: Ribavirin.

Open in New Tab Full Size Figure Download Figure

Figure 2 Sustained virological response by per-protocol analysis from sofosbuvir/velpatasvir with or without ribavirin. SOF/VEL: Sofosbuvir/velpatasvir; RBV: Ribavirin.

Open in New Tab Full Size Figure Download Figure

Figure 3 Severe adverse events from sofosbuvir/velpatasvir with or without ribavirin. SOF/VEL: Sofosbuvir/velpatasvir; RBV: Ribavirin.

Citation: Loo JH, Xu WXF, Low JT, Tay WX, Ang LS, Tam YC, Thurairajah PH, Kumar R, Wong YJ. Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis. World J Hepatol 2022; 14(6): 1248-1257
URL: https://www.wjgnet.com/1948-5182/full/v14/i6/1248.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i6.1248